Points to Consider No. 14: Manufacturing of ATMPs – Facility Design (Part 1)

NEW
Published
Nov 2025
ISBN
978-1-945584-51-0
Pages
62
PDA Item Number
43596
Format
PDF Single User
Member Price
$180.00
Nonmember Price
$325.00
Government Price
$180.00

*Premium members: Download your free copy by 12/17/2025!*

This Points to Consider document considers the facility, utilities, and process equipment designs necessary to support the manufacture and testing of ATMP therapies (autologous and allogeneic). Ideally, the design considerations should be weighed upfront to ensure the process meets the respective requirements. This document is organized into topics and various subtopics that address the questions raised about ATMP manufacture. Each question first presents an overall recommendation, which may be followed by a rationale for the recommendation and/or appropriate references for further reading.

 

Table of Contents

  • Topic 1. Risk Management
  • Topic 2. Facilities
  • Topic 3. Utilities
  • Topic 4. Process Equipment
  • Topic 5. Supplementary Technical Information
  • Recommended Reading
  • References

About the Authors

  • Richard Denk, SKAN AG (Lead)
  • Rebecca Brewer, Quality Executive Partners
  • Subrata Chakraborty, Gxpfont
  • Palash Das, Baxter
  • Alberto Gonzales, Takeda
  • Mark Hallworth, Particle Measuring
  • Rakesh Jakkashetty, SaudiBio
  • Lizette Janse van Rensburg, Eurolab
  • Claudia Lee, Velvet Therapeutics
  • Gerry McKiernan, CellTherapie
  • Juergen Metzger, Sartorius
  • Tracy Moore, TM Pharma Group
  • Youwen Pan, WuXi Biologics
  • Jean-Sebastien Parisse, Aseptic Technologies
  • David Phasey, 3P innovation
  • Durga Prasad Madhavapeddi, FUJIFILM Diosynth Biotechnologies
  • John Rapi, NNIT
  • Gilli Rosenzweig, Avrobio
  • Osamu Shirokizawa, Life Scientia, Ltd.
  • Andiyanto Sutandar, NNIT
  • Tricia Vail, Sartorius
  • Hartmut F. Zimmerman, Boehringer Ingelheim